解毒化瘀法治疗毒瘀交阻型胃癌前病变临床研究
|
摘要
目的观察解毒化瘀法治疗毒瘀交阻型胃癌前病变(PLGC)的临床疗效。方法将190例PLGC患者随机分为治疗组及对照组各95例,治疗组91例予以特定处方用药煎剂治疗,对照组87例予以维酶素片口服,2月为1疗程,3个疗程后比较两组患者症状积分变化,评价临床疗效。结果治疗组有效率82.42%,对照组有效率68.97%,治疗组疗效优于对照组,其差异有统计学意义(P<0.05)。治疗前后症状积分比较,治疗组在改善胃痛、痞胀、灼热、纳差、嘈杂等症状疗效优于对照组,差异有统计学意义(P <0.01,P<0.05)。结论解毒化瘀法对毒瘀交阻型PLGC患者的临床症状有明显改善作用,有待进一步推广应用。
Objective To observe the clinical effect of "Detoxification and Phlegm Resolving Method" in the treatment of Precancerous Lesions of Gastric Cancer(PLGC).Methods 190 patients with PLGC were randomly divided into treatment group and control group. The treatment group was treated with specific prescription decoction, while the control group was treated with vermectin tablets orally. The course of treatment was 2 months. After 3 courses, the changes of symptom scores were compared between the two groups, and the clinical efficacy was evaluated. Results The effective rate of the treatment group was 82.42%, and that of the control group was 68.97%. The curative effect of the treatment group was better than that of the control group, and the difference was statistically significant(P > 0.05). Comparing the scores of symptoms before and after treatment, the curative effect of the treatment group was better than that of the control group in improving the symptoms of stomachache, swelling, burning, nausea, noise, etc.(P < 0.01, P < 0.05). Conclusion "Detoxification and phlegm resolving method" has a significant improvement effect on the clinical symptoms of PLGC patients with toxin-stasis interaction, which needs further promotion and application.
Objective To observe the clinical effect of "Detoxification and Phlegm Resolving Method" in the treatment of Precancerous Lesions of Gastric Cancer(PLGC).Methods 190 patients with PLGC were randomly divided into treatment group and control group. The treatment group was treated with specific prescription decoction, while the control group was treated with vermectin tablets orally. The course of treatment was 2 months. After 3 courses, the changes of symptom scores were compared between the two groups, and the clinical efficacy was evaluated. Results The effective rate of the treatment group was 82.42%, and that of the control group was 68.97%. The curative effect of the treatment group was better than that of the control group, and the difference was statistically significant(P > 0.05). Comparing the scores of symptoms before and after treatment, the curative effect of the treatment group was better than that of the control group in improving the symptoms of stomachache, swelling, burning, nausea, noise, etc.(P < 0.01, P < 0.05). Conclusion "Detoxification and phlegm resolving method" has a significant improvement effect on the clinical symptoms of PLGC patients with toxin-stasis interaction, which needs further promotion and application.
引文
[1]VENERITO M,LINK A,ROKKAS T A.Gastric cancer clinical and epidemiological aspects[J].Helicobacter,2016,21(SI) :39-44.
[2]林依娜.中药治疗慢性萎缩性胃炎临床疗效的Meta分析[J].陕西中医药大学学报,2018,41(4):52-58.
[3]房静远,杜奕奇,刘文忠,等.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学,2017,22(11):670-687.
[4]李军祥,陈誩,吕宾,等.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[5]王捷虹,沈舒文,刘力,等.中医辨证治疗胃癌前期病变的临床观察与体会[J].辽宁中医杂志,2013,40(1):105-107.
[6]沈舒文,惠建萍,刘力,等.胃癌前病变虚实标本兼治的临床疗效研究[J].世界科学技术(中医药现代化),2012,17(1):1247-1251.
[7]伏沿蓉,张佳,王捷虹,等.慢性萎缩性胃炎中医治疗进展[J].陕西中医药大学报,2017,40(4):134-136.
[8] 惠建萍,沈舒文,刘力,等.从“毒瘀交阻”理论辨治胃癌前病变的思路与方法[J].世界科学技术(中医药现代化),2012,17(1):1270-1272.
[9]张万岱.导言:加强胃癌前病变的监测和防治研究[J].医学与哲学,2015,36 ( 11B) :9.
[10] 沈舒文,惠建萍,宇文亚,等.Study on Canceration Law of Gastric Mucosal Dysplasia Based on Syndromes of Chinese Medicine[J].Chinese Journal of Integrative Medicine,2011,(5):346-350.
[11]杨沙,段灿灿,晏仁义,等.基于网络药理学的半枝莲抗肿瘤活性成分及整合作用机制研究[J].中草药,2018,49(15):3471-3482.
[12]张韡,李忠.枸橘苷对胃癌细胞抑制作用及其机制研究[J].中国病理生理杂志,2017,33(9):1637-1642.
[13]赵勤,卫昊,胡锐,等.朱砂七总蒽醌对 S180 荷瘤小鼠凋亡基因表达的影响[J].天津中医药,2013,30(10):609-611
[14]崔奕,郑亮.郑亮教授论治慢性萎缩性胃炎临证撷要[J].陕西中医药大学学报,2018,41(1):18-20.
[15] 张德英,侯卓成,李卫强.中医药治疗胃癌前病变研究进展[J].辽宁中医杂志,2016,43(1) :207-210.
[2]林依娜.中药治疗慢性萎缩性胃炎临床疗效的Meta分析[J].陕西中医药大学学报,2018,41(4):52-58.
[3]房静远,杜奕奇,刘文忠,等.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学,2017,22(11):670-687.
[4]李军祥,陈誩,吕宾,等.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[5]王捷虹,沈舒文,刘力,等.中医辨证治疗胃癌前期病变的临床观察与体会[J].辽宁中医杂志,2013,40(1):105-107.
[6]沈舒文,惠建萍,刘力,等.胃癌前病变虚实标本兼治的临床疗效研究[J].世界科学技术(中医药现代化),2012,17(1):1247-1251.
[7]伏沿蓉,张佳,王捷虹,等.慢性萎缩性胃炎中医治疗进展[J].陕西中医药大学报,2017,40(4):134-136.
[8] 惠建萍,沈舒文,刘力,等.从“毒瘀交阻”理论辨治胃癌前病变的思路与方法[J].世界科学技术(中医药现代化),2012,17(1):1270-1272.
[9]张万岱.导言:加强胃癌前病变的监测和防治研究[J].医学与哲学,2015,36 ( 11B) :9.
[10] 沈舒文,惠建萍,宇文亚,等.Study on Canceration Law of Gastric Mucosal Dysplasia Based on Syndromes of Chinese Medicine[J].Chinese Journal of Integrative Medicine,2011,(5):346-350.
[11]杨沙,段灿灿,晏仁义,等.基于网络药理学的半枝莲抗肿瘤活性成分及整合作用机制研究[J].中草药,2018,49(15):3471-3482.
[12]张韡,李忠.枸橘苷对胃癌细胞抑制作用及其机制研究[J].中国病理生理杂志,2017,33(9):1637-1642.
[13]赵勤,卫昊,胡锐,等.朱砂七总蒽醌对 S180 荷瘤小鼠凋亡基因表达的影响[J].天津中医药,2013,30(10):609-611
[14]崔奕,郑亮.郑亮教授论治慢性萎缩性胃炎临证撷要[J].陕西中医药大学学报,2018,41(1):18-20.
[15] 张德英,侯卓成,李卫强.中医药治疗胃癌前病变研究进展[J].辽宁中医杂志,2016,43(1) :207-210.